Genemarkers provides collaborative services that enhance the utilization of genomics for improving health care, pharmaceutical research and consumer products. We take pride in providing high quality data and customer service. Our strength lies in our flexibility and personalized approach, allowing Genemarkers to meet the unique needs of each of our clients.
Pharmacogenomics (PGX) testing is rapidly emerging in clinical practice as medicine moves from a one-size-fits-all model to a precision medicine approach. PGX testing is used to:
Distinguished psychiatrist David Brendel, MD, PhD is a medical consultant for Genemarkers. Dr. Brendel is a Harvard trained, Board certified psychiatrist who specializes in treating individuals with impulse control disorders, bipolar disorder, major depression, psychosis, anxiety, [...]
Genemarkers, now powered by MedTek21, delivers more clinical decision support tools for pharmacogenomic (PGX) testing results. This partnership will assist providers with more actionable information needed to prescribe safer, more-effective medications and doses for their [...]
Genemarkers is proud to sponsor this year's Gryphon Place Suicide Prevention Walk. The 4th annual event will be held on Saturday, September 9th at Bronson Park in Kalamazoo, MI, coinciding with National Suicide Prevention Week. The [...]
Genemarkers CEO Dr. Anna Langerveld recently joined the Advisory Board for the Master of Science in Pharmacogenomics Program at Manchester University. Manchester is the first university to offer a one-year Master of Science in Pharmacogenomics, [...]
Genomic Testing for Improving Opioid Prescribing for Pain Management and Treatment of Opioid Use Disorder
Collaboration with Kalamazoo Community Mental Health & Substance Abuse Services and Ferris State University School of Pharmacy, funded by Michigan Department of Health & Human Services
Evaluation of the Clinical Utility of Pharmacogenomic (PGX) Testing in Community Mental Health Patients in Michigan
Collaboration with Western Michigan University Homer Stryker MD School of Medicine (WMed), Kalamazoo Community Mental Health & Substance Abuse Services and Ferris State University, funded by private donation to WMed.
Evaluation of Asymptomatic Coronary Atherosclerotic Disease among People of Michigan (ESCAPE) Michigan Trial
Collaboration with Borgess Hospital Heart Center for Excellence and Western Michigan University Homer Stryker MD School of Medicine.